Cantor Fitzgerald Issues Pessimistic Forecast for Semler Scientific (NASDAQ:SMLR) Stock Price

Key Points

• Cantor Fitzgerald has lowered their price target for Semler Scientific (NASDAQ:SMLR) from $61.00 to $60.00, while maintaining an "overweight" rating, indicating a potential upside of 73.81% from its current price.
• Other brokerages have varied opinions on SMLR, with one raising its rating to "strong-buy" and a new target price of $95.00, while another downgraded the stock to "sell," showing a lack of consensus among analysts.
• Semler Scientific reported earnings of $5.04 per share for the last quarter, significantly beating the consensus estimate of (\$0.27) per share and generating revenue of $8.22 million.

Semler Scientific (NASDAQ:SMLR - Get Free Report) had its target price lowered by investment analysts at Cantor Fitzgerald from $61.00 to $60.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Cantor Fitzgerald's price objective indicates a potential upside of 62.82% from the company's previous close.

SMLR has been the subject of several other reports. Wall Street Zen cut Semler Scientific from a "buy" rating to a "sell" rating in a report on Thursday, May 22nd. Benchmark assumed coverage on shares of Semler Scientific in a research note on Tuesday, July 8th. They issued a "buy" rating and a $101.00 price objective on the stock. Finally, Maxim Group upgraded shares of Semler Scientific to a "strong-buy" rating and set a $95.00 target price for the company in a research report on Wednesday, July 9th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Semler Scientific has an average rating of "Moderate Buy" and a consensus target price of $81.75.

Semler Scientific Stock Performance

NASDAQ SMLR traded down $0.69 on Wednesday, hitting $36.85. 156,740 shares of the company's stock were exchanged, compared to its average volume of 690,566. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.51. The firm's 50-day moving average price is $37.51 and its two-hundred day moving average price is $39.56. The firm has a market cap of $545.75 million, a price-to-earnings ratio of 15.17 and a beta of 1.34. Semler Scientific has a fifty-two week low of $21.77 and a fifty-two week high of $81.56.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $5.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $5.31. Semler Scientific had a net margin of 86.20% and a return on equity of 43.84%. The business had revenue of $8.22 million during the quarter, compared to the consensus estimate of $8.10 million.

Hedge Funds Weigh In On Semler Scientific

Several institutional investors and hedge funds have recently modified their holdings of SMLR. BNP Paribas Financial Markets purchased a new stake in Semler Scientific in the 4th quarter worth approximately $30,000. NewEdge Advisors LLC grew its position in shares of Semler Scientific by 318.3% in the fourth quarter. NewEdge Advisors LLC now owns 732 shares of the company's stock valued at $40,000 after purchasing an additional 557 shares during the period. Summit Securities Group LLC acquired a new position in Semler Scientific in the first quarter valued at $32,000. SBI Securities Co. Ltd. lifted its position in Semler Scientific by 161.3% during the first quarter. SBI Securities Co. Ltd. now owns 959 shares of the company's stock worth $35,000 after buying an additional 592 shares during the period. Finally, Legal & General Group Plc lifted its position in Semler Scientific by 65.4% during the fourth quarter. Legal & General Group Plc now owns 2,056 shares of the company's stock worth $111,000 after buying an additional 813 shares during the period. Hedge funds and other institutional investors own 49.37% of the company's stock.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.